Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss

Hagens Berman filed a securities class action against Erasca, Inc. (NASDAQ: ERAS) for alleged federal securities law violations. The lawsuit stems from Revolution Medicines accusing Erasca of patent infringement regarding ERAS-0015 pan-RAS therapy and a patient death following treatment. Class period covers January 14, 2025 to April 26, 2026. Erasca's stock dropped 48% ($9.25) after disclosures, eliminating $2.8 billion market cap. Lead plaintiff deadline is August 10, 2026.